Atopic dermatitis in 2008

Current Directions in Autoimmunity

Volumn 10, Issue , 2008, Pages 76-118

  Chan, L ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ALLERGEN; CYTOKINE; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ALLELE; ANIMAL; ANTIGEN PRESENTING CELL; ATOPIC DERMATITIS; CAUCASIAN; CLASSIFICATION; DISEASE MODEL; EPIDERMIS; GENETICS; HUMAN; IMMUNOLOGY; INFANT; INFLAMMATION; MUTATION; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; REVIEW; T LYMPHOCYTE;

ALLELES; ALLERGENS; ANIMALS; ANTIGEN-PRESENTING CELLS; CHILD, PRESCHOOL; CYTOKINES; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; EPIDERMIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; T-LYMPHOCYTES;

EID: 49049113962     PISSN: 14222132     EISSN: 16622936     Source Type: Book Series    
DOI: 10.1159/000131450     Document Type: Review

References (158)

1. Wuthrich B: What is atopy? Condition, disease, or a syndrome?; in Wuthrich B (ed): The Atopy Syndrome in the Third Millennium. Curr Probl Dermatol. Basel, Karger, 1999, vol 28, pp 1-8.
2. Coca AF, Cooke RA: On the classification of the phenomena of hypersensitiveness. J Immunol 1923;8:153-182.
3. Wise F, Sulzberger MB: Footnote on problem of eczema, neurodermatitis and lichenification; in Weis F, Sulzberger MB (eds): The 1933 Year Book of Dermatology and Syphiology. Chicago, Year Book, 1933, pp 38-39.
4. Stiftler WC: A 21 year follow-up of infantile eczema. J Pediatr 1965;66:166-169.
5. Musgrove K, Morgan JK: Infantile eczema: a long-term follow-up study. Br J Dermatol 1976;95:365-372.
6. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92:44-47.
7. Williams H: Disease definition and measures of disease frequency. J Am Acad Dermatol 2001;45:S33-S36.
8. William HC: What is atopic dermatitis and how should it be defined in epidemiological studies?; in Williams HC (ed): Atopic Dermatitis. Cambridge, Cambridge University Press, 2000, pp 3-24.
9. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB: Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-1095.
10. Ring J: Perspectives of atopic eczema in the third millennium; in Wuthrich B (ed): The Atopy Syndrome in the Third Millennium. Curr Probl Dermatol. Basel, Karger, 1999, vol 28, pp 192-204.
11. Flohr C, Johansson SGO, Wahlgren C-F, Williams H: How atopic is atopic dermatitis? J Allergy Clin Immunol 2004;114:150-158.
12. Schmid-Grendelmeier P, Simon D, Simon H-U, Akdis CA, Wuthrich B: Epidemiology, clinical features, and immunology of the 'intrinsic' (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001;56:841-849.
13. Novak N, Bieber T: Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252-262.
14. Wuthrich B, Schmid-Grendelmeier P: The atopic eczema/dermatitis syndrome: epidemiology, natural course, and immunology of the IgE-associated ('extrinsic') and the nonallergic ('intrinsic') AEDS. J Investig Allergol Clin Immunol 2003;13:1-5.
15. Oppel T, Schuller E, Gunther S, Moderer M, Heberstok J, Bieber T, Wollenberg A: Phenotyping of epidermal dendritic cells allows the differentiation between extrinsic and intrinsic forms of atopic dermatitis. Br J Dermatol 2000;143:1193-1198.
16. Novak N, Kruse S, Kraft S, Geiger E, Kluken H, Fimmers R, Deichmann KA, Bieber T: Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol 2002;119:870-875.
17. Jeong CW, Ahm KS, Rho NK, Park YD, Lee DY, Lee JH, Lee ES, Yang JM: Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy 2003;33:1717-1724.
18. Rho NK, Kim WS, Lee DY, Lee JH, Lee ES, Yang JM: Immunophenotyping of inflammatory cells in lesional skin of the extrinsic and intrinsic types of atopic dermatitis. Br J Dermatol 2004;151:119-125.
19. Park JH, Choi YL, Namkung JH, Kim WS, Lee JH, Park HJ, Lee ES, Yang JM: Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006;155:778-783.
20. Kusel MM, Holt PG, de Klerk N, Sly PD: Support for 2 variants of eczema. J Allergy Clin Immunol 2005;116:1067-1072.
21. Folster-Holst R, Pape M, Buss YL, Christophers E, Weichenthal M: Low prevalence of the intrinsic form of atopic dermatitis among adult patients. Allergy 2006;61:629-632.
22. Zachary CB, Allen MH, MacDonald DM: In situ quantitation of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol 1985;112:149-156.
23. Sillevis Smitt JH, Bos JD, Hulsebosch HJ, Krieg SR: In situ immunophenotyping of antigen presenting cells and T cell subsets in atopic dermatitis. Clin Exp Dermatol 1986;11:159-168.
24. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML: Predominance of 'memory' T cells (CD4+-, CDw2+-) over 'naïve' T cells (CD4+-, CD45R+-) in both normal and diseased human skin. Arch Dermatol Res 1989;281:24-30.
25. Santamaria Babi LF, Picker LJ, Perez Soler MT, Drzimalla K, Flohr P, Blaser K, Hauser C: Circulating antigen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med 1995;181:1935-1940.
26. Picker LJ, Michie SA, Rott LS, Butcher EC: A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-1068.
27. Akdis M, Akdis CA, Weigl L, Disch R, Blaser K: Skin-homing, CLA+- memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern. J Immunol 1997;159:4611-4619.
28. van der Heijden FL, Wierenga EA, Bos JD, Kapsenber ML: High frequency of IL-4-producing CD4+- allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991;97:389-394.
29. Lambrecht BN: Allergen uptake and presentation by dendritic cells. Curr Opin Allergy Clin Immunol 2001;1:51-59.
30. Taylor RS, Baadsgaard O, Hammerberg C, Cooper KD: Hyperstimulatory CD1a-+CD1b-+ CD36+- Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis. J Immunol 1991;147:3794-3802.
31. Kopf M, Gros GL, Bachmann M, Lamers MC, Bluethmann H, Kohler G: Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-248.
32. Grewe M, Fyufko K, Schopf E, Krutmann J: Lesional expression of interferon-γ in atopic eczema. Lancet 1994;343:25-26.
33. Nakazawa M, Sugi N, Kawaguchi H, Ishii N, Nakajima H, Minami M: Predominance of type 2 cytokine-producing CD4-+ and CD8+- cells in patients with atopic dermatitis. J Allergy Clin Immunol 1997;99:673-682.
34. Chan SC, Li S-H, Hanifin JM: Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993;100:681-684.
35. Tang MLK, Kemp AS: Spontaneous expression of IL-4 mRNA is lymphocytes from children with atopic dermatitis. Clin Exp Immunol 1994;97:491-498.
36. Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL: Overexpression of IL-10 in atopic dermatitis. J Immunol 1995;154:1956-1963.
37. Marone G, Casolaro V, Cirillo R, Stellato C, Genovese A: Pathophysiology of human basophils and mast cells in allergic disorders. Clin Immunol Immunopathol 1989;50:S24-S40.
38. Novak N, Kruse S, Potreck J, Maintz L, Jenneck C, Weidinger S, Fimmers R, Bieber T: Single nucleotide polymorphisms of the IL18 gene are associated with atopic dermatitis. J Allergy Clin Immunol 2005;115:828-833.
39. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H, Dieu-Nosjean MC, Meller S, Rieker J, Steinhoff M, Hoffmann TK, Ruzicka T, Zlotnik A, Homey B: IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-417.
40. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC, Merk HF, Bosio A, Baron JM, Hermanns HM: Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006;118:930-937.
41. Cooper D, Hales J, Camp R: IgE-dependent activation of T cells by allergen in atopic dermatitis: pathophysiologic relevance. J Invest Dermatol 2004;123:1086-1091.
42. Fisher PM, Buckley RH: Human IgE biosynthesis in vitro: studies with atopic and normal blood mononuclear cells and subpopulations. J Immunol 1979;123:1788-1794.
43. Ohman S, Johansson SG: Immunoglobulins in atopic dermatitis with special reference to IgE. Acta Derm Venereol 1974;54:193-202.
44. Schon MP, Zollner TM, Boehncke WH: The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003;121:951-962.
45. Steinhoff M, Steinhoff A, Homey B, Luger TA, Schneider SW: Role of vasculature in atopic dermatitis. J Allergy Clin Immunol 2006;118:190-197.
46. Jung K, Linse F, Heller R, Moths C, Goebel R, Neumann C: Adhesion molecules in atopic dermatitis: VCAM-1 and ICAM-1 expression is increased in healthy-appearing skin. Allergy 1996;51:452-460.
47. de Vries IJ, Langeveld-Wildschut EG, van Reijsen FC, Dubois GR, van den Hoek JA, Bihari IC, van Wichen D, de Weger RA, Knol EF, Thepen T, Bruijnzeel-KIoomen CA: Adhesion molecule expression on skin endothelia in atopic dermatitis: effects of TNF-α and IL-4. J Allergy Clin Immunol 1998;102:461-468.
48. Sigudsson V, de Vries IJ, Toonstra J, Bihari IC, Thepen T, Bruijnzeel-Koomen CA, van Vloten WA: Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol 2000;27:436-440.
49. Madej A, Reich A, Orda A, Szepietowski JC: Expression of vascular adhesion protein-1 in atopic eczema. Int Arch Allergy Immunol 2006;139:114-121.
50. Jung K, Imhof BA, Linse R, Wollina U, Neumann C: Adhesion molecules in atopic dermatitis: upregulation of α6 integrin expression in spontaneous lesional skin as well as in atopen, antigen and irritative induced patch test reactions. Int Arch Allergy Immunol 1997;13:495-504.
51. Pivarcsi A, Homey B: Chemokine networks in atopic dermatitis: traffic signals of disease. Curr Allergy Asthma Rep 2005;5:284-290.
52. Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, Dewald B, Braathen LR, Baggiolini M: Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 1999;113:43-48.
53. Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S, Toda M, Hamid QA: Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol 2000;105:1002-1007.
54. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG: A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+- lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000;115:640-646.
55. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, Harada S, Fukunaga A, Chantry D, Gray PW, Morita A, Suzuki R, Tezuka T, Ichihashi M, Yoshie O: IFN-γ-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol 2002;14:767-773.
56. h2-type chemokine and its receptor in atopic dermatitis. Int Immunol 2002;14:1431-1438.
57. Shimada Y, Takehara K, Sato S: Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 2004;34:201-208.
58. Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, Tada Y, Wakugawa M, Watanabe T, Torii H, Komine M, Asahina A, Nakamura K, Tamaki K: Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003;111:592-597.
59. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, Knol E: Serum thymus and activation chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atoic dermatitis. J Allergy Clin Immunol 2004;113:334-340.
60. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF: Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clin Exp Dermatol 2004;29:293-296.
61. Gunther C, Bello-Fernandez C, Kopp T, Kund J, Carballido-Perrig N, Hinterregger S, Fassi S, Schwarzler C, Lametschwandtner G, Stingl G, Biedermann T, Carballido JM: CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005;174:723-728.
62. Nakayama T, Jujisawa R, Yamada H, Horikawa T, Kawasaki H, Hieshima K, Izawa D, Jujiie S, Tezuka T, Yoshie O: Induced expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 α/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol 2001;13:95-103.
63. Gombert M, Dieu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, Da Cunha L, Haahtela A, Lehtimaki S, Muller A, Rieker J, Meller S, Pivarcsi A, Koreck A, Fridman WH, Zentgraf HW, Pavenstadt H, Amara A, Caux C, Kemeny L, Alenius H, Lauerma A, Ruzicka T, Zlotnik A, Homey B: CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 2005;174:5082-5091.
64. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Nakamura K, Takekoshi T, Kishimoto M, Mitsui H, Torii H, Komine M, Asahina A, Tamaki K: Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity and atopic dermatitis. Clin Exp Immunol 2003;134:309-311.
65. Kagami S, Saeki H, Komine M, Kakinuma T, Tsunemi Y, Nakamura K, Sasaki K, Asahina A, Tamaki K: Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Clin Exp Immunol 2005;141:459-466.
66. Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S: Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J Allergy Clin Immunol 2004;113:940-948.
67. Sumimoto B, Kawai M, Kasajima Y, Hamamoto T: Increased plasma tumor necrosis factor-α concentration in atopic dermatitis. Arch Dis Child 1992;67:277-279.
68. Antunez C, Torres MJ, Mayorga C, Cornejo-Garcia JA, Santamaria-Babi LF, Blanca M: Different cytokine production and activation marker profiles in circulating cutaneous-lymphocyte-associated antigen T cells from patients with acute and chronic atopic dermatitis. Clin Exp Allergy 2004;34:559-566.
69. Lomholt H, Andersen KE, Kilian M: Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J Invest Dermatol 2005;125:977-982.
70. Strange P, Skov L, Lisby S, Nielsen PL, Baadgaard O: Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. Arch Dermatol 1996;132:27-33.
71. Valenta R, Natter S, Seiberier S, Wichlas S, Maurer D, Hess M, Pavelka M, Grote M, Ferreira F, Szepfalusi Z, Valent P, Stingl G: Molecular characterization of an autoantigen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol 1998;111:1178-1183.
72. Aichberger KJ, Mittermann I, Reininger R, Seiberler S, Swoboda I, Spitzauer S, Kopp T, Stingl G, Sperr WR, Valent P, Repa A, Bohle B, Kraft D, Valenta R: Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity. J Immunol 2005;175:1286-1294.
73. Schmid-Grendelmeier P, Fluckiger S, Disch R, Trautmann A, Wuthrich B, Blaser K, Schevnius A, Crameri R: IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 2005;115:1068-1075.
74. Sugiura K, Muro Y, Nishizawa Y, Okamoto M, Shinohara T, Tomita Y, Usukura J: LEDGF/DFS70, a major autoantigen of atopic dermatitis, is a component of keratohyalin granules. J Invest Dermatol 2007;127:75-80.
75. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6.
76. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146.
77. Zhang Y, Matsuo H, Morita E: Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 2006;297:425-429.
78. Gutermuth J, Ollert M, Ring J, Behrendt H, Jakob T: Mouse models of atopic eczema critically evaluated. Int Arch Allergy Immunol 2004;135:262-276.
79. Zheng T, Zhu Z: Lessons from murine models of atopic dermatitis. Curr Allergy Asthma Rep 2005;5:291-297.
80. Sinke JD, Thepen T, Bihari IC, Rutten VP, Willemse T: Immunophenotyping of skin-infiltrating T-cell subsets in dogs with atopic dermatitis. Vet Immunol Immunopathol 1997;57:13-23.
81. Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB: Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clin Exp Allergy 2002;32:789-795.
82. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C: Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997;9:461-466.
83. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H, Matsushima K: Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 1999;104:1097-1105.
84. Chan LS (ed): Animal Models of Human Inflammatory Skin Diseases. Boca Raton, CRC Press, 2003.
85. Chan LS: Skin inflammatory disorders; in Stevenson CS, Marshall LA, Morgan DW (ed): In vivo Models of Inflammation. Basel, Birkhauser, 2006, pp 85-120.
86. Chan LS, Robinson N, Xu L: Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:977-983.
87. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS: Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 2004;138:375-387.
88. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS: Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 2005;139:189-201.
89. Chen L, Lin SX, Oberbergh L, Mathieu C, Chan LS: The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clin Exp Immunol 2005;142:21-30.
90. Chen L, Lin SX, Agha-Majzoub R, Overbergh L, Mathieu C, Chan LS: CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model. Int Immunol 2006;18:1233-1242.
91. Agha-Majzoub R, Becker RP, Schraufnagel DE, Chan LS: Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation 2005;12:455-476.
92. Chan LS, Gordon KB: Mouse immune system; in Chan LS (ed): Animal Models of Human Inflammatory Skin Diseases. Boca Raton, CRC Press, 2003, pp 119-140.
93. Bruynzeel-Koomen C, van der Donk EM, Bruynzeel PL, Capron M, de Gast GC, Mudde GC: Associated expression of CD1 antigen and Fc receptor for IgE on epidermal Langerhans cells from patients with atopic dermatitis. Clin Exp Immunol 1988;74:137-142.
94. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, Hanau D, de la Salle C: Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc RI). J Exp Med 1992;175:1285-1290.
95. Hayashi S, Matsuda H, Okumura K, Ra C: Mouse Langerhans cells do not express the high-affinity receptor for IgE. Arch Dermatol Res 1999;291:241-243.
96. Coffman RL, Savelkoul HF, Lebman DA: Cytokine regulation of immunoglobulin isotype switching and expression. Semin Immunol 1989;1:55-63.
97. Venkataramani P, Grzeszkiewicz T, Lin S, Prabhakar B, Chan LS: An animal model of atopic dermatitis: lesional skin immunophenotyping delineates a CD4+- T cell-predominated inflammatory infiltrate associated with upregulation of adhesion molecules. J Invest Dermatol 2003;121:44.
98. Frontezak-Baniewicz M, Walski M: Non-sprouting angiogenesis in neurohypophysis after traumatic injury of the cerebral cortex: electron microscopic studies. Neuroendocrinol Lett 2002;23:396-404.
99. Masuda H, Kawamura K, Nanjo H, Sho E, Komatsu M, Sugiyama T, Sugita A, Asari Y, Kobayashi M, Ebina T, Hoshi N, Singh TM, Xu C, Zarins CK: Ultrastructure of endothelial cells under flow alteration. Microsc Res Tech 2003;60:2-12.
100. Schraufnagel DE, Arzouman DA, Sekosan M, Ho YK: The effect of transforming growth factor-α on airway angiogenesis. J Thorac Cardiovasc Surg 1992;104:1582-1588.
101. Burri PH, Djonov V: Intussusceptive angiogenesis - the alternative to capillary sprouting. Mol Aspects Med 2002;23:S1-S27.
102. Morita K, Sasaki H, Furuse K, Furuse M, Tsukita S, Miyachi Y: Expression of claudin-5 in dermal vascular endothelia. Exp Dermatol 2003;12:289-295.
103. Wollenberg A, Wetzel S, Burgdorf WH, Haas J: Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003;112:6678-6674.
104. Parslew R, Verbov JL: Kaposi's varicelliform eruption due to herpes simplex in Darier's disease. Clin Exp Dermatol 1994;19:428-429.
105. Flint ID, Spencer DM, Wilkin JK: Eczema herpeticum in association with familial benign chronic pemphigus. J Am Acad Dermatol 1993;28:257-259.
106. Pantazi V, Potouridou I, Katsarou A, Papadogiorgaki TH, Katsambas A: Darier's disease complicated by Kaposi's varicelliform eruption due to herpes simplex virus. J Eur Acad Dermatol 2000;14:209-211.
107. Donnelly AA, Butler R, Miller CH: A case of Kaposi varicelliform eruption in Darier-White disease. Cutis 2005;75:33-36.
108. Bestue M, Cordero A: Kaposi's varicelliform eruption in a patient with healing peribucal dermabrasion. Dermatol Surg 2000;26:939-940.
109. Bartralot R, Garcia-Patos V, Rodriguez-Cano L, Castells A: Kaposi's varicelliform eruption in a patient with healing second degree burns. Clin Exp Dermatol 1996;21:127-130.
110. Lane JM, Goldstein J: Adverse events occurring after smallpox vaccination. Semin Pediatr Infect Dis 2003;14:189-195.
111. Di Nardo A, Wertz P, Giannetti A, Seidenari S: Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998;78:27-30.
112. Ohnishi Y, Okino N, Ito M, Imayama S: Ceramidase activity in bacterial skin flora as a possible cause ceramide deficiency in atopic dermatitis. Clin Diagn Lab Immunol 1999;6:101-104.
113. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G: High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000;115:406-413.
114. Macheleidt O, Kaiser HW, Sandhoff K: Deficiency of epidermal protein-bound -hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002;119:166-173.
115. Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S: Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol 2007;127:129-134.
116. Chamlin SL, Frieden HJ, Fowler AJ, Williams M, Kao J, Sheu M, Elias PM: Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001;137:1110-1112.
117. Chamlin SL, Kao J, Frieden HJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM: Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
118. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichidawa Y, Imokawa G: Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphyloccocus aureus. J Invest Dermatol 2002;119:433-439.
119. Jones CA, Holloway JA, Popplewell EH, Diaper ND, Holloway JW, Vance GH, Warner JA, Warner JO: Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. J Allergy Clin Immunol 2002;109:858-866.
120. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, Werfel T, Herz U, Heeg K, Neumaier M, Renz H: The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004;113:565-567.
121. Weidinger S, Klopp N, Aummier L, Wagenpfeil S, Novak N, Baurecht HJ, Groer W, Darsow U, Heinrich J, Gauger A, Schafer T, Jakob T, Behrendt H, Wichmann HE, Ring J, Illig T: Association of NOD1 polymorphisms with atopic eczema and related phenotype. J Allergy Clin Immunol 2005;116:177-184.
122. Rieg S, Steffen H, Seeber S, Humeny A, KKalbacher H, Dietz K, Garbe C, Schittek B: Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 2005;174:8003-8010.
123. Kim BE, Leung DY, Streib JE, Boguniewicz M, Hamid QA, Howell MD: Macrophage inflammatory protein 3α deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J Allergy Clin Immunol 2007;119:457-463.
124. Wells RS, Kerr CS: Clinical features of autosomal dominant and sex-linked ichthyosis in an English population. Br Med J 1966;1:947-950.
125. Kuokkanen K: Ichthyosis vulgaris: a clinical and histopathological study of patients and their close relatives in the autosomal dominant and sex-linked forms of the disease. Acta Derm Venereol Suppl (Stockh) 1969;62:1-72.
126. Tay YK, Khoo BP, Goh CL: The epidemiology of atopic dermatitis at a tertiary referral skin center in Singapore. Asian Pac J Allergy Immunol 1999;17:137-141.
127. Smith FJD, Irvine AD, Terron-Kaiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WHI: Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337-342.
128. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, Tezuka T: Decreased expression of filaggrin in atopic skin. Arch Dermatol Res 1996;288:442-446.
129. Gan SQ, McBride OW, Idler WW, Markova N, Steinert PM: Organization, structure, and polymorphisms of the human profilaggrin gene. Biochemistry 1990;29:9432-9440.
130. Candi E, Schmidt R, Melino G: The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005;6:328-340.
131. Listwan P, Rothnagel JA: Keratin bundling proteins. Methods Cell Biol 2004;78:817-827.
132. Taieb A: Hypothesis: from epidermal barrier dysfunction to atopic dermatitis. Contact Dermatitis 1999;41:177-180.
133. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE, Coleman R, Leaves NI, Trembath RC, Moffatt MF, Harper JI: Genetic linkage of childhood atopic dermatitis in psoriasis susceptibility loci. Nat Genet 2001;27:372-373.
134. Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, Schutze S, Proksch E: Impaired sphinogomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004;122:1423-1431.
135. Sugiura H, Ebise H, Tazawa T, Tanaka K, Sugiura Y, Uehara M, Kikuchi K, Kimura T: Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br J Dermatol 2005;152:146-149.
136. Palmer CAN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJD, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WHI: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
137. Bisgaard H: The Copenhagen prospective study on asthma in childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol 2004;93:381-389.
138. Mohrenschlager M, Darsow U, Schnopp C, Ring J: Atopic dermatitis: what's new? J Eur Acad Dermatol Venereol 2006;20:503-511.
139. Schlessinger J, Miller B, Gilbert RD, Plott RT: An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol 2006;142:1568-1572.
140. Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, Murrell DF, Gebauer K, Bechre U, Machura E, Olafsson J, Szalai Z: Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006;91:905-910.
141. Caproni M, Torchia D, Antiga E, Volpi W, del Bianco E, Fabbri P: The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006;26:370-375.
142. Hoetzenecker W, Meindl S, Stuetz A, Singl G, Elbe-Burger A: Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis. J Invest Dermatol 2006;126:2141-2144.
143. Weissenbacher S, Traidl-Hoffmann C, Eyerich K, Katzer K, Braeutigam M, Loeffler H, Hofmann H, Behrendt H, Ring J, Darsow U: Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006;140:239-244.
144. Berger TG, Duvic M, van Voorhees AS, Van Beek MJ, Frieden IJ: The use of topical calcinruin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-823.
145. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK: Tarcolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol 2005;152:1173-1181.
146. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:1276-1283.
147. Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU: Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 2005;60:944-951.
148. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU: Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004;114:887-895.
149. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ: Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005;53:S206-S213.
150. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, van Voorhees AS: Guideline of care for atopic dermatitis. J Am Acad Dermatol 2004;50:391-404.
151. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger jS, Werfel T, Zuberbier T; European Academy of Allergology and Clinical Immunology/Amcerican Academy of Allegy, Asthma and Immunology: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
152. Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, Boehm G: A mixture of prebiotics oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child 2006;91:814-819.
153. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A: Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-395.
154. Passeron T, Lacour JP, Fontas E, Ortonne JP: Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 2006;61:431-437.
155. Elsner J, Escher SE, Forssmann U: Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004;59:1243-1258.
156. D'Amato G, Liccardi G, Noschese P, Salzillo A, D'Amato M, Cazzola M: Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets Inflamm Allergy 2004;3:227-229.
157. Schmitt J, Wozel G, Pfeiffer C: Leflunomide as a novel treatment option in severe atopic dermatitis. Br J Dermatol 2004;150:1182-1185.
158. Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalnao N, O'Garra A, Oshida T, Saito H, Johnston JA, Yoshimura A, Kubo M: SOCS-3 regulates onset and maintenance of TH2-mediated allergic responses. Nat Med 2003;9:1047-1054.